A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING DOSE STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF CC 220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

被引：0
|
作者：
Furie, R. [1 ]
Werth, V. P. [2 ,3 ]
Lee, E. [4 ]
Box, E. [5 ]
Fondal, M. [6 ]
Kivitz, A. [7 ]
Chatham, W. W. [8 ]
Kalunian, K. C. [9 ]
Legerton, C. [10 ]
Anolik, J. H. [11 ]
Korish, S. [12 ]
Hough, D. R. [12 ]
Weiswasser, M. [12 ]
Choi, S. [12 ]
Schafer, P. [12 ]
机构：
[1] Hofstra Northwell Sch Med, Northwell Hlth, Div Rheumatol, New Hyde Pk, NY USA
[2] Hosp Univ Penn, Dept Dermatol, 3400 Spruce St, Philadelphia, PA 19104 USA
[3] Vet Adm Med Ctr, Philadelphia, PA 19104 USA
[4] Inland Rheumatol Clin Trials Inc, Upland, CA USA
[5] Carolinas PLLC, Box Arthrit & Rheumatol, Charlotte, NC USA
[6] Arthrit Res & Treatment Ctr, Stockbridge, GA USA
[7] Altoona Ctr Clin Res, Duncansville, PA USA
[8] Univ Alabama Birmingham, Rheumatol & Clin Immunol, Birmingham, AL USA
[9] UC San Diego Hlth, Div Rheumatol, San Diego, CA USA
[10] Low Country Rheumatol PA, Charleston, SC USA
[11] Univ Rochester, Med Ctr, Div Allergy Immunol & Rheumatol, Rochester, NY 14642 USA
[12] Celgene Corp, Summit, NJ USA
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2016年 / 34卷 / 04期
关键词：
CC-220; Ikaros; cereblon;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P5:94
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [21] Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis
    Akin, Cem
    Mdphd
    Elberink, Hanneke Oude
    Gotlib, Jason
    Sabato, Vito
    Hartmann, Karin
    Broesby-Olsen, Sigurd
    Castells, Mariana
    Tashi, Tsewang
    Heaney, Mark L.
    George, Tracy I.
    Siebenhaar, Frank
    Radia, Deepti H.
    Triggiani, Massimo
    van Daele, Paul
    DeAngelo, Daniel J.
    Alvarez-Twose, Ivan
    Reiter, Andreas
    Vadas, Peter
    Bonadonna, Patrizia
    Hew, Paggy
    Lin, Hui-Min
    Roche, Maria
    Maurer, Marcus
    BLOOD, 2020, 136
  • [22] Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
    Stohl, William
    Schwarting, Andreas
    Okada, Masato
    Scheinberg, Morton
    Doria, Andrea
    Hammer, Anne E.
    Kleoudis, Christi
    Groark, James
    Bass, Damon
    Fox, Norma Lynn
    Roth, David
    Gordon, David
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (05) : 1016 - 1027
  • [23] Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study
    Kuah, D.
    Sivell, S.
    Longworth, T.
    James, K.
    Guermazi, A.
    Cicuttini, F.
    Wang, Y.
    Craig, S.
    Comin, G.
    Robinson, D.
    Wilson, J.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [24] Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study
    D. Kuah
    S. Sivell
    T. Longworth
    K. James
    A. Guermazi
    F. Cicuttini
    Y. Wang
    S. Craig
    G. Comin
    D. Robinson
    J. Wilson
    Journal of Translational Medicine, 16
  • [25] A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome
    Nyhlin, H
    Bang, C
    Elsborg, L
    Silvennoinen, J
    Holme, I
    Rüegg, P
    Jones, J
    Wagner, A
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2004, 39 (02) : 119 - 126
  • [26] A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation
    Webster, Lynn
    Dhar, Sunita
    Eldon, Michael
    Masuoka, Lorianne
    Lappalainen, Jaakko
    Sostek, Mark
    PAIN, 2013, 154 (09) : 1542 - 1550
  • [27] A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
    Wallace, Daniel J.
    Stohl, William
    Furie, Richard A.
    Lisse, Jeffrey R.
    McKay, James D.
    Merrill, Joan T.
    Petri, Michelle A.
    Ginzler, Ellen M.
    Chatham, W. Winn
    McCune, W. Joseph
    Fernandez, Vivian
    Chevrier, Marc R.
    Zhong, Z. John
    Freimuth, William W.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (09): : 1168 - 1178
  • [28] A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
    Targan, Stephan R.
    Feagan, Brian G.
    Vermeire, Severine
    Panaccione, Remo
    Melmed, Gil Y.
    Blosch, Consuelo
    Newmark, Richard
    Zhang, Nan
    Chon, Yun
    Lin, Shao-Lee
    Klekotka, Paul
    GASTROENTEROLOGY, 2012, 143 (03) : E26 - E26
  • [29] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    Wallace, Daniel J.
    Furie, Richard A.
    Tanaka, Yoshiya
    Kalunian, Kenneth C.
    Mosca, Marta
    Petri, Michelle A.
    Doerner, Thomas
    Cardiel, Mario H.
    Bruce, Ian N.
    Gomez, Elisa
    Carmack, Tara
    DeLozier, Amy M.
    Janes, Jonathan M.
    Linnik, Matthew D.
    de Bono, Stephanie
    Silk, Maria E.
    Hoffman, Robert W.
    LANCET, 2018, 392 (10143): : 222 - 231
  • [30] A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
    Robert Bissonnette
    Catherine Maari
    Athanasios Tsianakas
    DeAnne Reid
    Sara McCutchan
    Scott Baumgartner
    James Mackay
    Nihar Bhakta
    Dermatology and Therapy, 2021, 11 : 2179 - 2193
12345